drugset / Trial / NCT05353192
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
Phase 4
Unknown
38 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Chengdu Women's and Children's Central Hospital · collabChildren's Hospital of Fudan University · collabChildren's Hospital of Nanjing Medical University · collabChildren's Hospital of The Capital Institute of Pediatrics · collabJiangxi Province Children's Hospital · collabShandong Provincial Hospital · collabShanghai Children's Hospital · collabShengjing Hospital · collabTongji Hospital · collabWest China Second University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia
Timeline
- Start
- 2022-09-23
- Primary completion
- 2025-02
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 0.05 mg/kg | Subcutaneous |